Results of a completely outpatient autologous stem cell transplant program for lymphoma patients receiving reduced-intensity conditioning

References

• Schmitz N, Pfistner B, Sextro M, Lymphoma Working Party of the European Group for Blood and Marrow Transplantation, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065–2071.
   PubMed Web of Science ®Google Scholar
• Weingart O, Rehan FA, Schulz H, et al. Sixth biannual report of the Cochrane Haematological Malignancies Group-focus on non-Hodgkin lymphoma. J Natl Cancer Inst. 2007;99(17):E1.
   PubMedGoogle Scholar
• Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant. 2015;50(8):1037–1056.
   PubMed Web of Science ®Google Scholar
• Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21(11):1863–1869.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Loberiza FRJ, Zhang MJ, et al. Autotransplants for Hodgkin’s disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant. 2001;27(4):387–396.
   PubMed Web of Science ®Google Scholar
• Garfin PM, Link MP, Donaldson SS, et al. Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution. Biol Blood Marrow Transplant. 2015;21(2):326–334.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Boumendil A, Finel H, et al. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. Bone Marrow Transplant. 2016;51(3):365–371.
   PubMed Web of Science ®Google Scholar
• Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–132.
   PubMed Web of Science ®Google Scholar
• Reddy NM, Oluwole O, Greer JP, et al. Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma. Exp Hematol. 2014;42(1):39–45.
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles GJ. Lessons learned starting a bone marrow transplantation programme in a resource-constrained setting. Lancet Haematol. 2020;7(7):e509-10–e510.
   Web of Science ®Google Scholar
• Chen YB, Lane AA, Logan BR, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1046–1053.
   PubMed Web of Science ®Google Scholar
• Sellner L, Boumendil A, Finel H, EBMT Lymphoma Working Party, et al. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: A retrospective study from the EBMT. Bone Marrow Transplant. 2016;51(2):212–218.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Lobato LG, Martínez-Roca A, Moreno DF, et al. Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients. Leuk Lymphoma. 2020;61(7):1565–1574.
   PubMed Web of Science ®Google Scholar
• Scortechini I, Montanari M, Mancini G, et al. Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma. Leuk Lymphoma. 2014;55(7):1657–1660.
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664–3671.
   PubMed Web of Science ®Google Scholar
• Jaime-Pérez JC, Salazar-Cavazos L, Aguilar-Calderón P, et al. Assessing the efficacy of an ambulatory peripheral blood hematopoietic stem cell transplant program using reduced intensity conditioning in a low-middle-income country. Bone Marrow Transplant. 2019;54(6):828–838.
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M. The multinational association for supportive care in cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer. 2013;21(5):1487–1495.
   PubMed Web of Science ®Google Scholar
• Bains T, Chen AI, Lemieux A, et al. Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma. 2014;55(3):583–587.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Popat U, Anderlini P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome . Biol Blood Marrow Transplant. 2013;19(3):410–417.
   PubMed Web of Science ®Google Scholar
• Jaime-Pérez JC, Gamboa-Alonso CM, Padilla-Medina JR, et al. High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center. Rev Bras Hematol Hemoter. 2017;39(4):325–330.
   PubMedGoogle Scholar
• Roerden M, Sökler M, Kanz L, et al. Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma – a long-term follow-up single center experience. Ann Hematol. 2020;99(2):265–276.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Zhang MJ, Carreras J, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010;16(1):35–45.
   PubMed Web of Science ®Google Scholar
• Jaimovich G, Ostriz MBR, Castro M, et al. CBeV (cyclophosphamide, bendamustine and etoposide) pre-autotransplant conditioning in persons with lymphoma. Bone Marrow Transplant. 2020;55(1):265–267.
   PubMed Web of Science ®Google Scholar
• Isidori A, Christofides A, Visani G. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. Leuk Lymphoma. 2016;57(11):2499–2509.
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, et al. Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. Bone Marrow Transplant. 2005;36(8):715–720.
   PubMed Web of Science ®Google Scholar
• Coltoff A, Shreenivas A, Afshar S, et al. A single-institution experience of performing bloodless transplant in Jehovah's Witness patients. Hematol Oncol Stem Cell Ther. 2019;12(1):44–49.
   PubMedGoogle Scholar
• Leger C, Sabloff M, McDiarmid S, et al. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma. Ann Hematol. 2006;85(10):723–729.
   PubMed Web of Science ®Google Scholar
• Cazeau N, Cavalier K, Bhatt V, et al. Outpatient BEAM using daily etoposide and cytarabine with autologous hematopoietic stem cell transplantation for lymphoma is feasible and decreases inpatient length of stay. Blood. 2019;134(Supplement_1):5830–5830.
   Google Scholar
• Graff TM, Singavi AK, Schmidt W, et al. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone Marrow Transplant. 2015;50(7):947–953.
   PubMed Web of Science ®Google Scholar
• Berber I, Erkurt MA, Nizam I, et al. Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients: a single center experience. Int J Clin Exp Med. 2015;8(9):16308–16314.
   PubMed Web of Science ®Google Scholar
• Jaime‐Pérez JC, Heredia‐Salazar AC, Cantú‐Rodríguez OG, et al. Cost structure and clinical outcome of a stem cell transplantation program in a developing country: the experience in Northeast Mexico. Oncologist. 2015;20(4):386–392.
   PubMed Web of Science ®Google Scholar